Ibogaine

What is Ibogaine

Ibogaine is a hypnotic and aphrodisiac substance from an African shrub originating in the Congo and Gabon. It is frequently used in religious rituals.

Scientific research has shown that ibogaine has an unsuspected ability to treat the physical dependence associated with withdrawal symptoms of drugs such as heroin, methadone, and opiates. It relieves 90% of the symptoms of abstinence and at the same time restores the habitual patterns of thought and the correct functioning of neurochemistry of the brain.

Also ibogaine is beneficial for the treatment of addiction because it restores the areas of the brain related to pleasure and desire that are affected by the abuse of these drugs. At this time no other substance has been found capable of recovering these areas with such magnitude and precision. Ibogaine is non-addictive and does not need to be ingested regularly. It also has antidepressant properties giving the body a sense of wellbeing. Studies performed to find neurological effects have not found any negative effects when using ibogaine in doses practiced for the treatment of addiction.

Patients who have undergone treatment describe it as a trip where they may feel some unwanted effects, but they disappear within hours. Most feel nauseous, so it is important to remain as still as possible during the initial stages of therapy. Vomiting can last a few hours, while the body gets rid of physical and psychic toxins. Visual and auditory distortions may also occur during the first six hours, which completely disappear after the 36th hour. Periods of sleeplessness and/or a great discomfort may be experienced when waking up.

KNOW MORE ABOUT IBOCURE CENTER

Ibogaine

Ibogaine

ibo
ibo2

IBOCURE specialize in this type of treatment received by many patients in the United States, where ibogaine is illegal.

Although the FDA recognized in 1993 ibogaine as an effective tool for the treatment of addiction, the problem is money: the molecule cannot be patented and is not a drug with addictive properties, which discouraged investment in its development on the part of the pharmaceutical industry.